Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-Blinded, Active-Controlled Study of CB-183,315 in Patients With Clostridium Difficile Associated Diarrhea

Trial Profile

A Randomized, Double-Blinded, Active-Controlled Study of CB-183,315 in Patients With Clostridium Difficile Associated Diarrhea

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 14 Dec 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Surotomycin (Primary) ; Vancomycin
  • Indications Clostridium difficile infections; Diarrhoea; Intestinal infections
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms C-difficile
  • Sponsors Cubist Pharmaceuticals
  • Most Recent Events

    • 03 Aug 2020 Results of a pooled analysis of the data from the two phase III trials (NCT01597505 and NCT01598311) assessing the molecular epidemiology and antimicrobial susceptibility of Clostridioides difficile isolates from patients with C. difficile infection, published in the Journal of Antimicrobial Chemotherapy
    • 26 Feb 2018 A protocol has been amended with addition of primary safety endpoints and change in secondary endpoints.
    • 12 Apr 2016 Results assessing susceptibility and molecular epidemiology of Clostridium difficile presented at the 26th European Congress of Clinical Microbiology and Infectious Diseases
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top